drugset / Trial / NCT01322321

ACZ885 in Type 1 Diabetes Mellitus

NCT01322321

Phase 2 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.

Timeline

Start
2011-03
Primary completion
2011-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody